CLVS - Clovis Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.83
+0.28 (+1.92%)
As of 9:32AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close14.55
Open14.61
Bid0.00 x 3000
Ask14.98 x 800
Day's Range14.61 - 14.94
52 Week Range11.50 - 50.00
Volume19,374
Avg. Volume1,390,046
Market Cap786.061M
Beta (3Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-7.16
Earnings DateJul 30, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Trade prices are not sourced from all markets
  • AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
    Zacksyesterday

    AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use

    AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.

  • Markityesterday

    See what the IHS Markit Score report has to say about Clovis Oncology Inc.

    Clovis Oncology Inc NASDAQ/NGS:CLVSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CLVS are favorable, with net inflows of $2.62 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?
    Insider Monkey6 days ago

    Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?

    Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]

  • Benzinga12 days ago

    The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...

  • Business Wire13 days ago

    Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair

    “I am very pleased to announce that Ginger Graham is assuming the role of our Board Chair at Clovis Oncology. As an active Clovis board member for six years, Ginger is extremely familiar with our organization and will bring her tremendous expertise as a healthcare executive to her elevated role as Board Chair,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology.

  • Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report?
    Zacks13 days ago

    Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report?

    Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire18 days ago

    Expanded Rubraca® (Rucaparib) Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting

    BOULDER, Colo.-- -- In exploratory analysis of ARIEL3 data, Rubraca significantly improved clinically meaningful endpoints including chemotherapy free interval and PFS on next therapy line for women with advanced ovarian cancer in maintenance treatment setting Updated Rubraca safety profile was consistent with the safety profile previously observed in ARIEL3 TRITON2 findings show that tumor tissue ...

  • Biotech Stocks Clobbered As Two Slammed With Sell Ratings
    Investor's Business Daily21 days ago

    Biotech Stocks Clobbered As Two Slammed With Sell Ratings

    Clovis Oncology and Esperion Therapeutics stocks skidded Wednesday after an analyst downgraded the biotech companies to sell ratings amid rising competition in their respective markets.

  • Barrons.com21 days ago

    Clovis Oncology Stock Sinks on Dim View of Cancer Drug Sales

    Shares of the biotech firm sank Wednesday morning after an analyst at Goldman Sachs downgraded the stock from Neutral to Sell.

  • Business Wirelast month

    Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®▼ in Advanced Ovarian Cancer

    Quality-adjusted progression free survival and quality-adjusted time without cancer related symptoms or toxicity demonstrate the benefit of Rubraca maintenance t

  • Business Wirelast month

    Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting

    Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CLVS earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 Clovis Oncology Inc Earnings Call

  • Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
    Zackslast month

    Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong

    Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.

  • Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript

    CLVS earnings call for the period ending March 31, 2019.

  • Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates
    Zackslast month

    Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates

    Clovis (CLVS) delivered earnings and revenue surprises of 9.44% and 4.53%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Clovis: 1Q Earnings Snapshot

    The Boulder, Colorado-based company said it had a loss of $1.63 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...

  • Business Wirelast month

    Clovis Oncology Announces First Quarter 2019 Operating Results

    BOULDER, Colo.-- -- $33.1M in Rubraca ® global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at Fall 2019 medical meeting Clovis-sponsored combination studies of lucitanib ...

  • Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
    Zackslast month

    Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?

    During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

  • What's in the Cards for Perrigo (PRGO) This Earnings Season?
    Zackslast month

    What's in the Cards for Perrigo (PRGO) This Earnings Season?

    Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.

  • Cronos (CRON) to Report Q1 Earnings: What's in the Cards?
    Zackslast month

    Cronos (CRON) to Report Q1 Earnings: What's in the Cards?

    Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when the company reports Q1 results.

  • Business Wirelast month

    Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2019

    Clovis Oncology, Inc. (CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2019 on Tuesday, May 14, 2019 at 2:20 PM Pacific Time. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

  • Here’s What Hedge Funds Think About About Clovis Oncology Inc (CLVS)
    Insider Monkey2 months ago

    Here’s What Hedge Funds Think About About Clovis Oncology Inc (CLVS)

    "October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]